Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660034 · ClinicalTrials.gov registry record · Phase 1
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 229
- Enrollment target
NCT02660034 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 229 participants.
The verdict
NCT02660034, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 229 participants
- Enrollment target
Study Summary
This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.
Interventions
- DRUG Pamiparib
- BIOLOGICAL Tislelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2016-02-02 |
| Est. Completion | 2020-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02660034
The ClinicalTrials.gov registry entry for NCT02660034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pamiparib is the first listed.
NCT02660034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02660034 about?
NCT02660034 is a clinical study titled "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors". This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advance...
What is the current status of trial NCT02660034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 229 participants. The study started on 2016-02-02. Estimated completion is 2020-09-09.
What interventions are being tested in trial NCT02660034?
The interventions under investigation include: Pamiparib (DRUG), Tislelizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02660034?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.